Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Quarterly results
|
|
ARATANA THERAPEUTICS, INC. (PETX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/08/2019 |
8-K
| Quarterly results |
| 11/01/2018 |
8-K
| Quarterly results |
| 08/02/2018 |
8-K
| Quarterly results |
| 05/03/2018 |
8-K
| Quarterly results |
| 11/02/2017 |
8-K
| Quarterly results |
| 08/03/2017 |
8-K
| Quarterly results |
| 05/08/2017 |
8-K
| Form 8-K - Current report |
| 11/03/2016 |
8-K
| Form 8-K - Current report |
| 08/04/2016 |
8-K
| Form 8-K - Current report |
| 05/05/2016 |
8-K
| Form 8-K - Current report |
| 11/05/2015 |
8-K
| Quarterly results |
| 08/06/2015 |
8-K
| Quarterly results |
| 05/07/2015 |
8-K
| Quarterly results |
| 11/10/2014 |
8-K
| Quarterly results|
Docs:
|
"Financial Results: For the three months ended September 30, 2014, Aratana reported a net loss of million, or basic earnings per share, compared to a loss of million for the same period in 2013. For the nine months ended September 30, 2014, the Company reported a net loss of million, or basic earnings per share versus million for the same period in 2013. The Company reported revenue of $0.04 million for the three months ended September 30, 2014 and a total of $0.5 million in revenue for the first nine months of 2014. In the third quarter of 2014, the revenue was primarily related to the recognition of license and collaboration fees and manufacturing services related to AT-004, the B-cell monoclonal antibody for lymphoma. For the nine month period, the revenue also included R&D collaboration..." |
|
| 08/12/2014 |
8-K
| Quarterly results |
| 05/14/2014 |
8-K
| Quarterly results |
| 11/13/2013 |
8-K
| Quarterly results |
| 08/12/2013 |
8-K
| Form 8-K - Current report |
|
|